Biosimilar infliximab for Behçet's syndrome: a case series.

Dincses E., Esatoglu S. N., Ozguler Y., Uygunoglu U., Hamuryudan V., Seyahi E., ...More

Clinical and experimental rheumatology, no.6, pp.111-115, 2019 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: Issue: 6
  • Publication Date: 2019
  • Journal Name: Clinical and experimental rheumatology
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.111-115
  • Istanbul University Affiliated: Yes


Objective. The efficacy and safety of biosimilar infliximab (bio-IFX) was shown in randomised controlled trials and it was approved for all indications of the reference product in several countries. However, a previous case series of 3 patients with Behcet's syndrome (BS) reported disappointing results. We aimed to share our experience with bio-IFX treatment in different types of organ involvement in patients with BS.